John Markels, Ph.D.

Vaccine Company, a wholly owned subsidiary of Eli Lilly and Company, was founded to bring next-generation antigen engineering to vaccine science. Our proprietary In Vivo Nanoparticle (IVN) technologies are designed to combine the strengths of mRNA and virus-like particle approaches to enable durable, multivalent immune responses to challenging viral targets. We are advancing a pipeline of preclinical and IND-enabling programs, led by a vaccine candidate for the prevention of infectious mononucleosis caused by Epstein-Barr virus.

Arcturus Therapeutics is a global late stage-clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

Vaccine Company, a wholly owned subsidiary of Eli Lilly and Company, was founded to bring next-generation antigen engineering to vaccine science. Our proprietary In Vivo Nanoparticle (IVN) technologies are designed to combine the strengths of mRNA and virus-like particle approaches to enable durable, multivalent immune responses to challenging viral targets. We are advancing a pipeline of preclinical and IND-enabling programs, led by a vaccine candidate for the prevention of infectious mononucleosis caused by Epstein-Barr virus.

Arcturus Therapeutics is a global late stage-clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases

For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. To learn more about Sangamo, visit the our website at www.sangamo.com.

The only non-sectarian girls'​ day school in New Jersey, Kent Place provides a rigorous and fulfilling education for more than 600 students in Kindergarten through Grade 12. KPS also offers a coed Junior Pre-Kindergarten and Pre-Kindergarten program, The Preschool at Kent Place. The 26-acre campus in Summit, New Jersey, draws families from more than 80 communities.